Login to Your Account



WHO'S KALLIKREIN NOW?

Wine corker: OPuS-1 bid wins for Biocryst in HAE, Dyax sips from phase IIa

By Randy Osborne
Staff Writer

Tuesday, May 27, 2014
Top-line success for Biocryst Pharmaceuticals Inc. in a phase IIa proof-of-concept trial called OPuS-1 (Oral ProphylaxiS-1) with oral kallikrein inhibitor BCX4161 against hereditary angioedema (HAE) brought competitor Dyax Corp. along for the ride, as backers of both companies guessed about what's in store for the busy therapeutic space.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription